Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 7,620.00
Bid: 7,627.00
Ask: 7,628.00
Change: 0.00 (0.00%)
Spread: 1.00 (0.01%)
Open: 7,517.00
High: 7,647.00
Low: 7,500.00
Yest. Close: 7,494.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

UPDATE 1-Oxford COVID-19 trial will look at interim Phase III data after 53 infections - investigator

Thu, 19th Nov 2020 11:28

(Adding details throughout)

By Alistair Bell and Kate Kelland

LONDON, Nov 19 (Reuters) - Oxford University will start an
initial analysis of data from its late-stage trial of the
experimental COVID-19 vaccine it is developing with AstraZeneca
after 53 infections among its volunteers, the study's
chief investigator said on Thursday.

The Oxford Vaccine Group's director, Andrew Pollard, said in
a media briefing there were "lots of cases" of infections in its
Phase III trial in Britain, Brazil and South Africa.

The first two sets of interim data from vaccine trials from
Pfizer and BioNTech last week and Moderna
on Monday were released after more than 90 infections
among volunteers.

Pfizer had planned to publish initial data after about 60
infections, but it exceeded its target after the big jump in
infections recently in the United States.

Pollard's comments came after data published on Thursday
showed the Oxford/AstraZeneca vaccine in Phase II studies
produced a strong immune response in older adults, suggesting
that those at higher risk of serious illness and death from
COVID-19 could be protected.

Pollard said there was no attempt to release the study in
the same week as those companies' data, the first from
late-stage vaccine trials, but rather the study happened to be
ready for publication.

Earlier on Thursday, he said he expected Phase III data to
be released by Christmas.

The Phase III results showing efficacy of the vaccine will
be released via AstraZeneca, in the same way they have been
published by other drugmakers over the past week or so, Pollard
said.

He said the trial would also publish the findings in a
peer-reviewed medical journal but initial data would likely be
released before then.
(Reporting by Alistair Smout and Kate Kelland; Writing by
Josephine Mason; Editing by Alex Richardson and Nick Macfie)

More News

EU has exported 37 mln more COVID-19 shots than its nations have received - sources

BRUSSELS, April 21 (Reuters) - The European Union has exported about 37 million more doses of COVID-19 vaccines than it has shared out among its own 27 countries, two sources told Reuters citing figures from the bloc's data.The EU is buying most o...

21 Apr 21 17:17

EXPLAINER-How worried should we be about blood clots linked to Astra, J&J vaccines?

(Adds details following EMA warning label for J&J vaccine)By John Miller and Ludwig BurgerZURICH, April 21 (Reuters) - European regulators said the benefits of using Johnson & Johnson's and AstraZeneca's COVID-19 vaccines outweigh risks, even as th...

21 Apr 21 16:54

UPDATE 2-U.S. FDA finds peeling paint, debris at U.S. plant making J&J's COVID-19 vaccine

(Adds details from the report, JNJ statement)April 21 (Reuters) - The U.S. Food and Drug Administration (FDA) said it had found problems including peeling paint and loose debris during inspections at a U.S. plant in Baltimore that makes Johnson & ...

21 Apr 21 14:56

UPDATE 3-Peeling paint, debris among problems found at U.S. plant making J&J COVID-19 vaccine -FDA

(Adds additional detail from FDA report and company press release)By Carl O'Donnell and Manas MishraApril 21 (Reuters) - A plant making Johnson & Johnson's COVID-19 vaccine must fix a long list of problems including peeling paint, poor sanitation ...

21 Apr 21 14:56

UPDATE 4-Peeling paint, unsanitary practices among issues at U.S. plant making J&J COVID-19 vaccine -FDA

(Adds expert comment, Emergent statement, background)By Carl O'Donnell and Julie SteenhuysenApril 21 (Reuters) - A U.S. plant that was making Johnson & Johnson's COVID-19 vaccine must fix a long list of problems including peeling paint and unsanita...

21 Apr 21 14:56

EU snubs extra 300 mln J&J, Astra shots in bet on Pfizer-source

* EU is not taking extra doses under existing contracts* No decision on whether EU may seek new AZ, J&J contracts* EU betting on mRNA vaccines, in talks for Pfizer mega-dealBy Francesco GuarascioBRUSSELS, April 21 (Reuters) - The European Union won't...

21 Apr 21 14:30

Wednesday broker round-up

(Sharecast News) - Avast: Canaccord initiates at buy with a target price of 550.0p.

21 Apr 21 12:35

AstraZeneca jab guidance change for under-30s has not caused hesitancy

AstraZeneca jab guidance change for under-30s has not caused hesitancy

21 Apr 21 11:50

India's Serum Institute to raise output to 100 mln AstraZeneca doses by July, not end-May

NEW DELHI, April 21 (Reuters) - The Serum Institute of India will be able to raise its monthly output of the AstraZeneca COVID-19 vaccine to 100 million doses by July from 60-70 million now, later than a previous timeline of end-May, its chief ex...

21 Apr 21 11:40

With enough supplies, Israel looks to re-route AstraZeneca vaccine delivery

* Israel bought enough vaccine from others, official says* Seeks to divert AstraZeneca shipment to other countries* Israel's vaccine rollout one of the fastest in the worldJERUSALEM, April 21 (Reuters) - Israel no longer wants AstraZeneca's COVID-19...

21 Apr 21 10:45

UPDATE 2-FTSE 100 ends higher on AstraZeneca, oil stock boost; Just Eat Takeaway slumps

(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window)* Just Eat Takeaway.com slips as Uber Eats plans German launch* UK inflation edges up as COVID-19 price hit begins to ease* UK home prices j...

21 Apr 21 09:10

Sri Lanka reports six cases of blood clots among AstraZeneca vaccine recipients, 3 dead

NEW DELHI, April 21 (Reuters) - Sri Lanka has found six cases of blood clots among recipients of the AstraZeneca COVID-19 vaccine, three of whom have died, Health Minister Pavithra Waniarachchi told parliament on Wednesday.Nearly a million people ...

21 Apr 21 08:48

India's Serum institute to sell AstraZeneca vaccine to private hospitals at $8/dose

NEW DELHI, April 21 (Reuters) - The Serum Institute of India said on Wednesday it would sell the AstraZeneca vaccine to the country's state governments at 400 rupees ($5.30) per dose and to private hospitals at 600 rupees ($7.95)."Furthermore, owi...

21 Apr 21 08:15

UPDATE 1-J&J to cooperate in study of rare clots linked to COVID-19 vaccine, German scientist says

(Adds details of collaboration, scientific paper)By John MillerZURICH, April 20 (Reuters) - A German scientist studying extremely rare blood clots linked to AstraZeneca's COVID-19 vaccine said on Tuesday Johnson & Johnson has agreed to work with h...

20 Apr 21 20:35

UPDATE 2-J&J to cooperate in study of rare clots linked to COVID-19 vaccine, German scientist says

(Adds details on class of vaccines)By John MillerZURICH, April 20 (Reuters) - A German scientist studying extremely rare blood clots linked to AstraZeneca's COVID-19 vaccine said on Tuesday Johnson & Johnson has agreed to work with him on the rese...

20 Apr 21 20:35

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.